Elizabeth Loggers, MD, PhD, medical oncologist, Seattle Cancer Care Alliance, discusses the role that she expects immunotherapy will play in the future treatment landscape of sarcoma.
Early Data Shows Axi-Cel’s Potential in Treating R/R Primary and Secondary CNS Lymphomas
June 13th 2024Findings from a phase 1 trial presented at ASCO showed that axicabtagene ciloleucel was safe with clinical activity seen among patients with relapsed/refractory primary and secondary central nervous system lymphoma.
Read More